The insulin market is heading for a shakeup. But patients may not benefit

(By Rebecca Robbins for STAT)

The insulin market, dominated by old drugs that have skyrocketed in price, is on the verge of a shakeup. Continue reading article here…….

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.